Navigation Links
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Date:7/12/2011

ty and mechanism of action of APD811; the potential of APD811 and orally bioavailable, non-prostanoid prostacyclin receptor agonists in general; future study and evaluation of APD811; Arena's commitment to advance its pipeline; the therapeutic indication of Arena's most advanced drug candidate; and Arena's beliefs, focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: there was a small safety margin from the no observed adverse effect level to significant adverse events in preclinical studies of APD811, and APD811 could have an unacceptable safety and efficacy profile in humans; the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena submits such response or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
2. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
11. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014  Advanced Medical Isotope ... company engaged primarily in the development of brachytherapy ... applications, today announced that a Life Sciences Discovery ... awarded for which AMIC is the commercialization partner.  ... (WSU) for the proposal titled "Optimized Injectable Radiogels ...
(Date:12/19/2014)... 2014  Monarch America Inc. (OTCQB: CANK) ("Monarch America" ... to provide this review of the Company,s recent achievements ... "Over this past year, we achieved many of ... proud to say that Monarch America is in a ... ever been," stated Eric Hagen , CEO of ...
(Date:12/19/2014)... 18, 2014  Sage Analytics ( www.sageanalytics.com ), ... for the testing of marijuana potency and moisture ... Luminary™ Profiler, the industry,s first product suite capable ... cost-effective, portable unit. Designed from the ... the cannabis industry, the Luminary™ Profiler utilizes specially ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... NEWARK, N.J., April 6, 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... that the New York Stock Exchange (the "NYSE") has notified ... rules due to the Company,s failure to timely file its ... Commission. Under NYSE rules, when a Company ...
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ... of modafinil tablets, a generic version of Teva,s Provigil® ... the Provigil® product.  Par acquired the U.S. marketing rights ... of Cephalon in 2011.  According to IMS Health data, ...
Cached Medicine Technology:American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2Par Pharmaceutical Begins Shipment of Generic Provigil® 2
(Date:12/21/2014)... December 21, 2014 As testosterone ... heart attacks, stroke and blood clots from using testosterone ... a new study shows that the male hormone testosterone ... In a study published in the Proceedings of the ... Amos-Landgraf examined a group of male rats with naturally ...
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation hosted ... Whittier offices. The Hope for the Holidays Toy Drive is ... their families during the holiday season. This year, the toy ... between both offices. This event continues to be successful year ... team, store managers and assistant managers came out and not ...
(Date:12/20/2014)... BambooIndustry.com is a professional company offering many kinds ... shown its new engineered bamboo flooring collection, and announced ... , BambooIndustry.com’s customers come from many countries in the ... the CEO of the company, the global bamboo flooring ... few years, and the demand for eco-friendly bamboo flooring ...
(Date:12/20/2014)... (PRWEB) December 21, 2014 MissyDress, a ... for all prom lovers. The business has drastically cut ... prom dresses to everyone until Jan. 30, 2015. Many ... dresses, sweetheart dresses, V-neck dresses, lace dresses, and more. ... are not there every day. Whether A-line princess prom ...
(Date:12/20/2014)... December 20, 2014 An improving macroeconomic ... have benefited the Massage Services industry over ... of industry products, the anticipated 1.0% annualized increase in ... provided consumers with the means to afford additional massages. ... a massage in a given year has declined from ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... did language evolve? While the answer might seem obvious ... and other students of communication have debated this question for ... that language is, in fact, poorly designed for communication. Such ... system that probably evolved for other reasons perhaps for ...
... earlier generations, and even the best perform less well. Researchers ... major long-term health impact. The conclusions about the physical ... schoolchildren,s performance in the 3 000-metre race from 1969 to ... Dyrstad at the University of Stavanger (UiS) have drawn on ...
... House effort to ensure that America,s military heroes receive care ... David Geffen School of Medicine at UCLA have pledged to ... care to help train physicians to meet the special needs ... Joining Forces, an initiative launched by first lady Michelle ...
... of two studies suggest that a new, investigational colorectal ... Mayo Clinic and Exact Sciences Inc. of Madison, Wis., ... noninvasive tests at detecting precancerous tumors (adenomas) and early-stage ... tens of thousands of Americans. Early detection is a ...
... made illegal in the UK in 2010, the street price of ... turn may have reduced use of the drug. New research ... mephedrone after it became illegal would switch to a new legal ... or on the Internet. They would be less deterred by ...
... electronic health records (EHRs) are rapidly becoming part of ... providers of care. In the first large study of ... of Nursing determined that nurses working with EHRs consistently ... outcomes for patients than nurses working in hospitals without ...
Cached Medicine News:Health News:MIT: The advantage of ambiguity in language 2Health News:MIT: The advantage of ambiguity in language 3Health News:Sitting it out 2Health News:Sitting it out 3Health News:UCLA joins forces with White House to meet unique needs of veterans, families 2Health News:UCLA joins forces with White House to meet unique needs of veterans, families 3Health News:UCLA joins forces with White House to meet unique needs of veterans, families 4Health News:New test offers greater accuracy in early detection of colorectal cancer 2Health News:New test offers greater accuracy in early detection of colorectal cancer 3Health News:Despite the risks, mephedrone users in the UK are ready to try the next legal high 2Health News:Better together - The RN and the EHR 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: